Suddenly the hottest thing in biopharma isn’t a new indication, disease target or modality—it’s manufacturing, and all of pharma is going to be vying for capacity and talent.
Shutdown Grows Closer as Trump Tells G.O.P. to Kill Spending Deal The bill Republicans and Democrats agreed on is in jeopardy after President-elect Trump condemned it three days before the ...
"As we reflect on a transformative 2024, we are proud to have achieved record transaction volumes and to have made significant progress with our fintech platforms, ALT5 Pay and Prime. These ...